Biotech Drugs:Where Are the Generics?

摘要

AFTER MUCH THRASHING around,the biotech industry is finally nearing consensus on what to call less expensive,generic-type alternatives to pricey biotech drugs.The preferred term is "follow-on protein products," or FOPPs.Good,that's settled.Now for the bad news:Without concerted action in Washington,patients in the U.S.won't get their hands on such products for years.The need for FOPPs couldn't be clearer.